Temporal Arteritis Market By Treatment Type (Corticosteroids, Biologics [IL-6 Inhibitors, JAK Inhibitors, Others]); By Diagnostic Modality (Temporal Artery Biopsy, Ultrasound, MRI Angiography, PET-CT); By End User (Hospitals, Specialty Clinics, Diagnostic Centers, ASCs); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Introduction And Strategic Context

The Global Temporal Arteritis Market will witness a robust CAGR of 5.8%, valued at USD 1.4 billion in 2024, and projected to reach USD 2.0 billion by 2030, confirms Strategic Market Research.

 

Temporal arteritis, also known as giant cell arteritis (GCA), is an inflammatory vascular disorder that primarily affects medium and large arteries, especially in older adults. It carries a high risk of complications such as irreversible vision loss and stroke if untreated, making timely diagnosis and intervention critical.

 

The strategic importance of this market between 2024 and 2030 is being shaped by several forces. First, the aging global population is directly expanding the addressable patient base, particularly in North America, Europe, and parts of Asia. Second, advancements in biologics and corticosteroid-sparing therapies are changing the treatment landscape. Third, improved diagnostic imaging—such as PET-CT, temporal artery ultrasound, and MRI angiography—is enabling earlier detection and better disease management.

 

From a policy standpoint, healthcare systems are becoming more focused on autoimmune and inflammatory disorders, with temporal arteritis gaining recognition in reimbursement frameworks and clinical guidelines. This is particularly visible in the U.S., where Medicare coverage of advanced biologics is widening, and in Europe, where treatment pathways are being standardized under rheumatology and neurology consortia.

 

The stakeholder ecosystem is diverse. Pharmaceutical manufacturers are driving innovation in monoclonal antibodies and immune-modulating drugs. Diagnostic firms are developing more precise imaging tools. Hospitals and specialty clinics are expanding rheumatology and vascular medicine units to handle growing patient demand. Meanwhile, payers and insurers are increasingly factoring in the long-term cost burden of untreated temporal arteritis, which often leads to blindness and hospitalizations.

 

Market Segmentation And Forecast Scope

The temporal arteritis market can be segmented along four key dimensions: treatment type, diagnostic modality, end user, and region. Each dimension reflects the balance between clinical urgency, long-term safety, and healthcare system economics in managing this chronic inflammatory disease.

By Treatment Type

The market has traditionally relied on corticosteroids, which remain the first-line therapy due to their rapid anti-inflammatory effect and established clinical familiarity. However, prolonged steroid exposure is associated with significant comorbidity risks, including diabetes, osteoporosis, and cardiovascular complications. As a result, the market is shifting toward steroid-sparing strategies, accelerating uptake of biologic and targeted immune therapies.

• Corticosteroids: Continue to represent the majority of prescriptions in 2024 due to accessibility, low cost, and immediate symptom control. Despite dominance, growth is constrained by long-term safety concerns and guideline-driven efforts to minimize cumulative steroid exposure.

• Biologics (IL-6 Inhibitors): Biologics, particularly IL-6 inhibitors such as tocilizumab, are the fastest-growing segment. Adoption is driven by strong clinical trial outcomes demonstrating reduced relapse rates and steroid dependence, along with expanding payer acceptance for high-risk and recurrent patient populations.

• Emerging Targeted Therapies (JAK Inhibitors and Novel Immune Modulators): Smaller pipelines are exploring JAK inhibitors and other immune-modulating agents, positioned as long-term maintenance options with steroid-sparing potential. While still emerging, these therapies represent a key innovation pathway as stakeholders seek oral, scalable, and durable disease control.

Expert Insight: The commercial center of gravity is shifting from short-term inflammation control to long-term relapse prevention. This favors biologics and next-generation targeted agents, especially as health systems weigh the downstream costs of steroid-associated complications.

 

By Diagnostic Modality

Diagnosis hinges on rapid identification to prevent irreversible complications, most notably vision loss and blindness. The diagnostic landscape is evolving from invasive confirmation toward non-invasive, imaging-led workflows that can accelerate time to treatment and improve patient throughput in real-world settings.

• Temporal Artery Biopsy (TAB): Historically considered the gold standard, but limited by invasiveness, procedural capacity constraints, and risk of false negatives due to skip lesions. TAB remains important in ambiguous cases, but its role is gradually narrowing as imaging advances.

• Ultrasound of Temporal Arteries: Gaining traction as a first-line diagnostic tool due to its non-invasive nature, rapid turnaround, and real-time visualization. As guidelines increasingly recognize ultrasound in routine workups, it is projected to be the fastest-growing modality, especially in systems prioritizing early triage and scalable diagnostics.

• MRI Angiography (MRA): Used for deeper vascular assessment, particularly when large-vessel involvement is suspected or when ultrasound findings are inconclusive. Adoption is rising in tertiary centers and complex referral pathways.

• PET-CT: Increasingly applied in complex cases and in suspected systemic or large-vessel disease, supporting whole-body vascular inflammation mapping. Growth is supported by specialized use, though adoption is constrained by cost and infrastructure requirements.

Expert Insight: The diagnostic market is increasingly shaped by the need to confirm disease quickly without delaying treatment. Ultrasound aligns best with this requirement, while MRA and PET-CT remain high-value tools for escalation and complex presentations.

 

By End User

End users include hospitals, specialty clinics (rheumatology and neurology), and diagnostic imaging centers. Utilization patterns reflect where patients initially present, where therapy is managed long-term, and how diagnostic workflows are reorganizing around imaging-led protocols.

• Hospitals: Dominate market utilization because acute cases frequently present through emergency departments, ophthalmology, or inpatient referral routes where immediate treatment initiation is prioritized. Hospitals also anchor access to TAB, high-complexity imaging, and multidisciplinary evaluation.

• Specialty Clinics (Rheumatology/Neurology): Expanding their footprint as biologics and targeted therapies shift care into long-term management pathways. Specialty clinics are increasingly central to relapse prevention, steroid tapering strategies, and maintenance therapy monitoring.

• Diagnostic Imaging Centers: Emerging as a meaningful contributor, particularly in Europe and parts of Asia, as non-invasive imaging becomes a preferred diagnostic option. These centers are increasingly positioned for early screening and rapid diagnostic confirmation, especially where ultrasound-led pathways are being scaled.

Expert Insight: As temporal arteritis care transitions from acute detection to chronic relapse management, utilization is gradually shifting from hospital-centric care toward specialist-led outpatient models, supported by imaging centers for rapid confirmation.

 

By Region

Regional adoption is influenced by demographic aging, diagnostic infrastructure maturity, biologics reimbursement, and specialist availability. While mature markets currently lead biologics penetration, emerging regions show momentum through improved access and guideline modernization.

• North America: Leads due to advanced healthcare infrastructure, high disease awareness, and strong reimbursement support for biologics. Higher diagnostic availability and specialist density accelerate both detection and escalation to steroid-sparing therapies.

• Europe: Follows closely, driven by standardized treatment protocols and strong adoption of non-invasive diagnostics. Imaging-led pathways, especially ultrasound-based workups, are expanding across health systems focused on cost-effective diagnostic flow.

• Asia Pacific: The fastest-growing region, reflecting rapid demographic aging and improving healthcare access in Japan, China, and South Korea. Growth is supported by expanding specialist care networks and increasing diagnostic imaging capacity.

• Latin America and the Middle East & Africa (LAMEA): Remain underpenetrated but show rising diagnostic capacity, largely enabled by public–private hospital collaborations. Uptake is expected to improve as imaging access expands and high-risk patient pathways become more formalized.

Expert Insight: Regional growth divergence is primarily driven by biologics reimbursement and imaging capacity. Markets that enable rapid diagnosis + steroid-sparing access will see the strongest value expansion over the forecast period.

 

Scope Note: While temporal arteritis is clinically categorized under vasculitis, it is increasingly being commercialized as a standalone therapeutic market. This is mainly due to the growing importance of biologics, which demand distinct payer strategies, real-world evidence generation, and clinical trial investments tailored to relapse prevention, steroid tapering outcomes, and long-term safety.

 

Market Trends And Innovation Landscape

The temporal arteritis market is at an inflection point where traditional steroid-heavy care models are being challenged by precision therapies and novel diagnostics. Several innovation trends are reshaping the next phase of growth.

Shift Toward Biologic Therapies

High-dose corticosteroids have been the backbone of treatment for decades, but their side effect burden is driving a clinical shift. Biologic drugs, particularly IL-6 inhibitors such as tocilizumab, are now being incorporated into treatment pathways as both induction and maintenance options. Rheumatologists are also closely monitoring JAK inhibitors and other immune-targeted drugs in late-stage clinical pipelines. One expert described it this way: “We’re moving from suppressing inflammation bluntly to interrupting the exact pathways that fuel it.”

 

Growing Use of Imaging in Diagnosis

Invasive temporal artery biopsies are giving way to more advanced imaging. High-resolution ultrasound, MRI angiography, and PET-CT are now central to early diagnosis. Guidelines in Europe are beginning to recognize ultrasound as an acceptable frontline diagnostic tool, reducing delays in care. This trend is particularly important because vision loss can occur within weeks if diagnosis is delayed.

 

Integration of AI in Diagnostic Imaging

Artificial intelligence is being piloted in vascular ultrasound and PET-CT interpretation to speed up detection and improve diagnostic accuracy. AI-enabled imaging platforms are helping radiologists identify vessel wall thickening and inflammation patterns that might otherwise be missed. These tools are particularly relevant in resource-limited regions where trained vasculitis specialists are scarce.

 

Steroid-Sparing Strategies Gaining Support

Beyond new drugs, there’s a strong clinical push toward reducing steroid exposure. Trials are evaluating combination approaches—short induction with steroids followed by biologics—to preserve efficacy while lowering long-term toxicity. Patient advocacy groups are also highlighting the importance of minimizing corticosteroid side effects, which often disrupt quality of life in older populations.

 

Expansion of Clinical Trials and Real-World Evidence

Pharma companies are investing in broader, multinational studies that track long-term outcomes beyond initial remission. Real-world data registries are being built in the U.S. and Europe to monitor how patients respond to biologics outside controlled trial settings. These insights are influencing payer decisions, especially around reimbursement for expensive biologics.

 

Emergence of Personalized Medicine Approaches

Biomarker-driven strategies are being tested to predict which patients are at highest risk of relapse or steroid dependency. This could reshape how therapies are prescribed—moving toward tailored regimens rather than one-size-fits-all steroid protocols.

 

Collaborative Ecosystem

Partnerships between pharmaceutical firms, diagnostic companies, and academic hospitals are accelerating innovation. For instance, collaborations in Europe are standardizing ultrasound protocols for temporal arteritis, while U.S.-based research centers are partnering with pharma to refine trial endpoints around vision preservation and relapse prevention.

 

Competitive Intelligence And Benchmarking

The competitive landscape for temporal arteritis is relatively concentrated but evolving quickly as biologics and advanced diagnostics gain traction. Unlike broader autoimmune markets, the number of dedicated therapies here is limited, which gives early innovators a strong position.

Roche (Genentech)

Roche is currently the dominant player through its IL-6 inhibitor tocilizumab, the first biologic widely approved for giant cell arteritis. Its strength lies in being the only targeted therapy with established real-world evidence and reimbursement backing in multiple regions. Roche has strategically expanded access by integrating patient support programs in Europe and North America, which makes it a benchmark company in this space.

 

Novartis

Novartis is active in autoimmune and inflammatory conditions, with trials assessing new biologics and potential steroid-sparing regimens for vasculitis. Its competitive edge comes from an expansive immunology pipeline and a strong global reach, especially in emerging markets where it leverages its established distribution network.

 

GlaxoSmithKline (GSK)

GSK has invested heavily in inflammatory disease research, with monoclonal antibodies targeting pathways relevant to vasculitis. While it does not yet have a leading marketed product in temporal arteritis, its biologics pipeline positions it as a serious contender over the next five to seven years.

 

AbbVie

AbbVie is exploring the application of JAK inhibitors and other immunomodulators in rare autoimmune disorders. Its strategy is to extend success from rheumatoid arthritis and related conditions into vasculitis markets, including temporal arteritis. AbbVie’s experience with payer negotiations also gives it a competitive advantage when introducing premium therapies.

 

Eli Lilly

Lilly’s strength comes from its diversified immunology portfolio and ongoing collaborations with academic researchers studying vasculitis. It has been actively expanding clinical trial footprints across Europe and North America, aiming to capture unmet demand for alternatives to corticosteroids.

 

Diagnostics Companies (Siemens Healthineers , GE HealthCare, Canon Medical Systems)

On the diagnostics side, leading imaging firms are competing through the development of vascular ultrasound platforms, PET-CT, and MRI angiography optimized for inflammatory vascular diseases. Siemens and GE are particularly strong in AI-enhanced vascular imaging, giving them an edge in regions where clinical expertise is limited.

 

Benchmarking Insights

• Roche remains the market leader because of first-mover advantage and established clinical trust.

• Novartis and GSK are emerging challengers, with pipelines that could diversify the therapeutic base by 2030.

• AbbVie and Lilly are positioned to leverage their immunology experience to secure a foothold.

• Diagnostic players form a parallel competitive landscape, where innovation in imaging is critical to early diagnosis and long-term disease monitoring.

 

Regional Landscape And Adoption Outlook

Adoption patterns for temporal arteritis therapies and diagnostics vary widely across regions, shaped by healthcare infrastructure, aging demographics, and access to biologics. While prevalence of the disease is relatively consistent in populations over 50, the approach to diagnosis and treatment diverges significantly.

North America

The United States leads in adoption, driven by high disease awareness and insurance coverage for biologics like tocilizumab. Medicare reimbursement has been a crucial enabler, particularly since temporal arteritis predominantly affects older adults. Hospitals and specialty clinics are increasingly adopting vascular ultrasound as a frontline diagnostic tool, reducing reliance on invasive biopsies. Canada mirrors this trend, though access to biologics is slightly more restricted due to provincial funding models.

 

Europe

Europe represents a stronghold of structured care, where temporal arteritis is recognized as a critical public health issue within rheumatology. Countries like the UK, Germany, and France have standardized protocols emphasizing non-invasive diagnostics and steroid-sparing treatment strategies. The European League Against Rheumatism (EULAR) plays an important role in harmonizing care pathways. Nordic countries in particular are ahead in integrating ultrasound into clinical guidelines, while Southern and Eastern Europe show slower adoption due to funding constraints.

 

Asia Pacific

This region is the fastest-growing market, though still emerging. Japan and South Korea are leading in diagnostic adoption, with advanced imaging facilities and early trial participation in biologics. China and India are seeing rising case detection as awareness of vasculitis expands among clinicians. However, access to biologics is uneven, with affordability remaining a major challenge. Private hospitals in urban centers are adopting advanced treatments faster, while rural healthcare systems still rely primarily on corticosteroids.

 

Latin America

Countries like Brazil and Mexico are beginning to integrate biologics into treatment protocols, but uptake is limited to large urban hospitals and private sector facilities. Public health systems remain largely dependent on corticosteroids due to cost barriers. Diagnostic capacity is improving, particularly in Brazil, where PET-CT and MRI angiography are being introduced in tertiary care hospitals.

 

Middle East and Africa

This region remains underpenetrated. In the Middle East, countries like Saudi Arabia and the UAE are building specialized rheumatology and vascular medicine units, which are adopting both advanced diagnostics and biologics. Africa, however, continues to rely heavily on corticosteroids, with access to biologics and advanced imaging restricted to a handful of teaching hospitals and NGO-supported facilities.

 

Regional Outlook

• North America and Europe dominate due to strong infrastructure, payer support, and guideline-driven adoption.

• Asia Pacific offers the fastest growth potential, fueled by demographic aging and expanding healthcare coverage.

• Latin America and Africa remain largely untapped, where affordability, training, and infrastructure gaps hold back widespread adoption.

 

End-User Dynamics And Use Case

The end-user base for temporal arteritis spans across hospitals, specialty clinics, and diagnostic centers. Each group interacts with the disease differently, depending on the stage of diagnosis, treatment complexity, and patient profile.

Hospitals

Hospitals remain the primary entry point for most temporal arteritis cases, particularly because patients often present with acute symptoms such as sudden vision loss, severe headaches, or stroke-like features. Emergency departments work closely with neurology, ophthalmology, and rheumatology teams to stabilize patients. Large hospitals are also at the forefront of biologic adoption, as they have the infrastructure for infusion centers and the ability to manage complex side effects of advanced therapies.

 

Specialty Clinics

Rheumatology and neurology clinics are critical for long-term disease management. These clinics handle the transition from high-dose corticosteroid induction to maintenance therapy with biologics or steroid-sparing regimens. They also conduct close monitoring of relapses, which are common in temporal arteritis. Clinics are often the sites where patient education takes place, helping older patients manage side effects and treatment adherence.

 

Diagnostic Centers

Imaging plays a growing role in temporal arteritis detection, and diagnostic centers are expanding their role as referral points for non-invasive testing. Ultrasound of the temporal arteries, PET-CT, and MRI angiography are increasingly ordered before or alongside biopsies. Outpatient diagnostic centers are becoming particularly important in Europe, where clinical guidelines encourage imaging as a first-line tool.

 

Ambulatory Surgical Centers (ASCs)

Though not a major segment, some ASCs play a role in performing temporal artery biopsies when imaging results are inconclusive. However, this share is expected to decline as imaging gains wider acceptance.

 

Use Case Highlight

A tertiary hospital in Germany faced increasing demand for early diagnosis of temporal arteritis as referrals from local clinics surged. Historically, patients were sent for invasive biopsies, leading to long wait times and delayed treatment. In 2023, the hospital invested in high-resolution vascular ultrasound units equipped with AI-assisted interpretation software. Within a year, biopsy demand fell by nearly 50%, diagnosis timelines shortened significantly, and early initiation of biologic therapies improved patient outcomes. Physicians also reported higher confidence in detecting large-vessel involvement, which previously went unnoticed.

This use case underscores the shift in end-user dynamics: hospitals and clinics are no longer managing temporal arteritis in isolation. Diagnostics, treatment, and monitoring are converging into an integrated care model that prioritizes speed, precision, and reduced reliance on invasive procedures.

 

Recent Developments + Opportunities & Restraints

Recent Developments (Last 2 Years)

• Roche expanded access to tocilizumab in 2023 through new reimbursement approvals in several European countries, strengthening its position as the first-line biologic for giant cell arteritis.

• Novartis initiated a Phase III trial in 2024 investigating an IL-17 inhibitor for vasculitis, signaling the entry of alternative biologic pathways into the market.

• Siemens Healthineers partnered with academic centers in 2023 to standardize vascular ultrasound protocols for non-invasive diagnosis of temporal arteritis across Europe.

• AbbVie announced an R&D collaboration with rheumatology clinics in North America in 2024 to evaluate the role of JAK inhibitors as steroid-sparing agents.

• A multi- center study in Japan (2023) validated PET-CT imaging as a reliable diagnostic option for detecting large-vessel involvement in temporal arteritis, potentially reshaping diagnostic standards.

 

Opportunities

• Growing demand for steroid-sparing therapies as clinicians and patients seek safer long-term management options.

• Expansion of non-invasive diagnostic imaging, especially vascular ultrasound and PET-CT, which reduce reliance on invasive biopsies.

• Rapid aging of global populations, particularly in Asia Pacific, creating a larger at-risk patient pool.

• Increasing payer willingness to reimburse biologics as evidence of reduced long-term costs becomes stronger.

 

Restraints

• High cost of biologics compared with corticosteroids, limiting adoption in low- and middle-income countries.

• Limited availability of trained specialists, especially in vascular ultrasound interpretation, creating diagnostic bottlenecks.

• Regulatory hurdles in approving new biologics for rare autoimmune diseases, which can delay market entry.

 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 1.4 Billion
Revenue Forecast in 2030	USD 2.0 Billion
Overall Growth Rate	CAGR of 5.8% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Treatment Type, By Diagnostic Modality, By End User, By Geography
By Treatment Type	Corticosteroids, Biologics (IL-6 Inhibitors, JAK Inhibitors, Others)
By Diagnostic Modality	Temporal Artery Biopsy, Ultrasound, MRI Angiography, PET-CT
By End User	Hospitals, Specialty Clinics, Diagnostic Centers, ASCs
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, Germany, UK, France, China, Japan, India, Brazil, etc.
Market Drivers	- Rising adoption of biologics and steroid-sparing therapies - Increasing use of non-invasive diagnostic imaging - Aging population leading to higher prevalence of temporal arteritis
Customization Option	Available upon request